Home/Filings/4/0001415889-24-009596
4//SEC Filing

Gillies Hunter 4

Accession 0001415889-24-009596

CIK 0001798749other

Filed

Mar 31, 8:00 PM ET

Accepted

Apr 1, 6:00 PM ET

Size

8.8 KB

Accession

0001415889-24-009596

Insider Transaction Report

Form 4
Period: 2024-03-28
Gillies Hunter
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-03-28$2.14/sh+9,000$19,26012,251 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-03-289,00089,510 total
    Exercise: $2.14Exp: 2031-04-01Common Stock (9,000 underlying)
  • Sale

    Common Stock

    2024-03-28$29.50/sh9,000$265,5003,251 total
Footnotes (2)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
  • [F2]A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.

Issuer

Aerovate Therapeutics, Inc.

CIK 0001798749

Entity typeother

Related Parties

1
  • filerCIK 0001868997

Filing Metadata

Form type
4
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 6:00 PM ET
Size
8.8 KB